JP2015531407A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015531407A5 JP2015531407A5 JP2015536826A JP2015536826A JP2015531407A5 JP 2015531407 A5 JP2015531407 A5 JP 2015531407A5 JP 2015536826 A JP2015536826 A JP 2015536826A JP 2015536826 A JP2015536826 A JP 2015536826A JP 2015531407 A5 JP2015531407 A5 JP 2015531407A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- cell
- modified
- ompt1
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 claims description 92
- 108090000623 proteins and genes Proteins 0.000 claims description 92
- 235000018102 proteins Nutrition 0.000 claims description 78
- 150000001413 amino acids Chemical class 0.000 claims description 51
- 235000001014 amino acid Nutrition 0.000 claims description 45
- 229940024606 amino acid Drugs 0.000 claims description 45
- 230000001580 bacterial effect Effects 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 30
- 230000015572 biosynthetic process Effects 0.000 claims description 26
- 238000003786 synthesis reaction Methods 0.000 claims description 26
- 239000000284 extract Substances 0.000 claims description 17
- 241000894006 Bacteria Species 0.000 claims description 15
- 108020005038 Terminator Codon Proteins 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 101710116435 Outer membrane protein Proteins 0.000 claims description 11
- 241000588724 Escherichia coli Species 0.000 claims description 7
- 230000010627 oxidative phosphorylation Effects 0.000 claims description 6
- 102000003712 Complement factor B Human genes 0.000 claims description 4
- 108090000056 Complement factor B Proteins 0.000 claims description 4
- 102000003960 Ligases Human genes 0.000 claims description 4
- 108090000364 Ligases Proteins 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 239000011541 reaction mixture Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 230000002934 lysing effect Effects 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- 108010049152 Cold Shock Proteins and Peptides Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000017278 Glutaredoxin Human genes 0.000 claims description 2
- 108050005205 Glutaredoxin Proteins 0.000 claims description 2
- 108010063907 Glutathione Reductase Proteins 0.000 claims description 2
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 102000001253 Protein Kinase Human genes 0.000 claims description 2
- 102000013090 Thioredoxin-Disulfide Reductase Human genes 0.000 claims description 2
- 108010079911 Thioredoxin-disulfide reductase Proteins 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 2
- 230000006037 cell lysis Effects 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 230000000593 degrading effect Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 239000006166 lysate Substances 0.000 claims description 2
- 102000035118 modified proteins Human genes 0.000 claims description 2
- 108091005573 modified proteins Proteins 0.000 claims description 2
- 108020000161 polyphosphate kinase Proteins 0.000 claims description 2
- 238000001243 protein synthesis Methods 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 230000014616 translation Effects 0.000 claims description 2
- -1 RF1 Proteins 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 239000003488 releasing hormone Substances 0.000 claims 2
- 238000010025 steaming Methods 0.000 claims 2
- 102000035195 Peptidases Human genes 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000000338 in vitro Methods 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261713245P | 2012-10-12 | 2012-10-12 | |
| US61/713,245 | 2012-10-12 | ||
| PCT/US2013/063804 WO2014058830A1 (en) | 2012-10-12 | 2013-10-08 | Proteolytic inactivation of select proteins in bacterial extracts for improved expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017229231A Division JP2018029621A (ja) | 2012-10-12 | 2017-11-29 | 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015531407A JP2015531407A (ja) | 2015-11-02 |
| JP2015531407A5 true JP2015531407A5 (cg-RX-API-DMAC7.html) | 2016-11-24 |
| JP6421122B2 JP6421122B2 (ja) | 2018-11-07 |
Family
ID=49447839
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015536826A Active JP6421122B2 (ja) | 2012-10-12 | 2013-10-08 | 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化 |
| JP2017229231A Withdrawn JP2018029621A (ja) | 2012-10-12 | 2017-11-29 | 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化 |
| JP2020173282A Withdrawn JP2021003134A (ja) | 2012-10-12 | 2020-10-14 | 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017229231A Withdrawn JP2018029621A (ja) | 2012-10-12 | 2017-11-29 | 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化 |
| JP2020173282A Withdrawn JP2021003134A (ja) | 2012-10-12 | 2020-10-14 | 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9650621B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2906592B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6421122B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102018863B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104837863B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013329464C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2887355C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2906592T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2694683T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE041721T2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL238095B (cg-RX-API-DMAC7.html) |
| PL (1) | PL2906592T3 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201502875VA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014058830A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201502875VA (en) | 2012-10-12 | 2015-06-29 | Sutro Biopharma Inc | Proteolytic inactivation of select proteins in bacterial extracts for improved expression |
| WO2014172631A2 (en) * | 2013-04-19 | 2014-10-23 | Sutro Biopharma, Inc. | Expression of biologically active proteins in a bacterial cell-free synthesis system using bacterial cells transformed to exhibit elevated levels of chaperone expression |
| US10316322B2 (en) * | 2014-07-02 | 2019-06-11 | Sutro Biopharma, Inc. | High growth capacity auxotrophic Escherichia coli and methods of use |
| CN108779446B (zh) * | 2016-01-13 | 2023-04-21 | 新英格兰生物实验室公司 | T7 rna聚合酶的热稳定变体 |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| CN106801047A (zh) * | 2016-12-30 | 2017-06-06 | 武汉金开瑞生物工程有限公司 | 一种通过无细胞蛋白合成系统制备半胱氨酸蛋白酶的方法 |
| KR20190103256A (ko) | 2016-12-30 | 2019-09-04 | 수트로박스, 인코포레이티드 | 비자연 아미노산을 갖는 폴리펩타이드-항원 접합체 |
| TW202426655A (zh) | 2017-07-11 | 2024-07-01 | 美商新索思股份有限公司 | 非天然核苷酸之導入及其方法 |
| BR112020002272A2 (pt) | 2017-08-03 | 2020-07-28 | Synthorx, Inc. | conjugados de citocina para o tratamento de doenças autoimunes |
| EA202090908A1 (ru) | 2017-10-12 | 2020-10-29 | Ваксайт, Инк. | Вакцина и связанные композиции для лечения пародонтита и способ применения |
| BR112020017016A2 (pt) | 2018-02-26 | 2020-12-29 | Synthorx, Inc. | Conjugados da il-15 e usos dos mesmos |
| JP7340591B2 (ja) * | 2018-07-11 | 2023-09-07 | アクティム・セラピューティクス・インコーポレイテッド | 遺伝子操作された免疫刺激性細菌菌株およびその使用 |
| CN108949796A (zh) * | 2018-07-27 | 2018-12-07 | 张家港市华天药业有限公司 | 一种用于合成谷胱甘肽的重组菌及谷胱甘肽的合成方法 |
| CN109055291A (zh) * | 2018-07-31 | 2018-12-21 | 张家港市华天药业有限公司 | 用于合成谷胱甘肽的重组菌及谷胱甘肽的合成方法 |
| BR112021005401A2 (pt) | 2018-11-08 | 2021-06-29 | Synthorx, Inc. | conjugados de interleucina 10 e usos dos mesmos |
| MA54952A (fr) | 2019-02-06 | 2022-05-11 | Synthorx Inc | Conjugués d'il-2 et méthodes d'utilisation de ceux-ci |
| BR112021019826A2 (pt) | 2019-04-02 | 2021-12-07 | Vaxcyte Inc | Síntese otimizada de antígeno de plasmídeo de invasão b livre de célula e composições e métodos de uso relacionados |
| TWI873169B (zh) | 2019-08-15 | 2025-02-21 | 美商欣爍克斯公司 | 使用il-2接合物之免疫腫瘤學組合療法 |
| CN114746122A (zh) | 2019-09-10 | 2022-07-12 | 新索思股份有限公司 | Il-2缀合物和治疗自身免疫性疾病的使用方法 |
| IL291786A (en) | 2019-11-04 | 2022-06-01 | Synthorx Inc | Interleukin 10 conjugates and their use |
| US12351850B2 (en) * | 2020-04-30 | 2025-07-08 | Sutro Biopharma, Inc. | Methods of producing full-length antibodies using E. coli |
| IL299074A (en) | 2020-06-25 | 2023-02-01 | Synthorx Inc | Immuno-oncology therapeutic combination with IL-2 and anti-AGFR antibody conjugates |
| EP4211156A1 (en) * | 2020-09-14 | 2023-07-19 | Sutro Biopharma, Inc. | Method for large scale production of antibodies using a cell-free protein synthesis system |
| BR112023006364A2 (pt) | 2020-10-09 | 2023-05-09 | Synthorx Inc | Terapia de combinação de imuno-oncologia com conjugados de il-2 e pembrolizumabe |
| EP4225375A1 (en) | 2020-10-09 | 2023-08-16 | Synthorx, Inc. | Immuno oncology therapies with il-2 conjugates |
| WO2022174102A1 (en) | 2021-02-12 | 2022-08-18 | Synthorx, Inc. | Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof |
| TW202245843A (zh) | 2021-02-12 | 2022-12-01 | 美商欣爍克斯公司 | Ｉｌ－２接合物及西米普利單抗（ｃｅｍｉｐｌｉｍａｂ）之皮膚癌組合療法 |
| CN113322267B (zh) * | 2021-03-15 | 2024-01-05 | 天津大学 | 系统在提高非天然氨基酸的插入效率中的应用 |
| TW202313679A (zh) | 2021-06-03 | 2023-04-01 | 美商欣爍克斯公司 | 包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法 |
| WO2023122573A1 (en) | 2021-12-20 | 2023-06-29 | Synthorx, Inc. | Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab |
| WO2023122750A1 (en) | 2021-12-23 | 2023-06-29 | Synthorx, Inc. | Cancer combination therapy with il-2 conjugates and cetuximab |
| WO2024136899A1 (en) | 2022-12-21 | 2024-06-27 | Synthorx, Inc. | Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies |
| TW202444349A (zh) | 2023-03-20 | 2024-11-16 | 美商欣爍克斯公司 | 使用ｉｌ－２綴合物之癌症療法 |
| WO2025015041A1 (en) * | 2023-07-12 | 2025-01-16 | University Of Washington | Rna-only, positive control target for clinical diagnostic testing |
| WO2025158385A1 (en) | 2024-01-25 | 2025-07-31 | Genzyme Corporation | Pegylated il-2 for suppressing adaptive immune response to gene therapy |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60040771D1 (de) * | 1999-03-04 | 2008-12-24 | Asubio Pharma Co Ltd | Verfahren zur kontrolle der spaltung mit ompt protease |
| WO2002059293A2 (en) | 2001-01-25 | 2002-08-01 | Forster Anthony C | Process and compositions for peptide, protein and peptidomimetic synthesis |
| WO2004016778A1 (en) | 2002-08-19 | 2004-02-26 | The Board Of Trustees Of The Leland Stanford Junior University | Improved methods of in vitro protein synthesis |
| DE10336705A1 (de) * | 2003-08-06 | 2005-03-10 | Rina Netzwerk Rna Technologien | Verfahren zur Herstellung eines Lysats zur zellfreien Proteinbiosynthese |
| ES2398463T3 (es) | 2003-09-30 | 2013-03-19 | Daiichi Sankyo Company, Limited | Método de escisión de polipéptidos usando un mutante de la proteasa OmpT |
| WO2006082059A1 (en) * | 2005-02-02 | 2006-08-10 | Universität Bayreuth | Esterases for monitoring protein biosynthesis in vitro |
| CN104789536A (zh) | 2005-10-12 | 2015-07-22 | 斯克利普斯研究院 | 噬菌体展示多肽的选择性翻译后修饰 |
| WO2007109035A2 (en) * | 2006-03-16 | 2007-09-27 | The Scripps Research Institute | Genetically programmed expression of proteins containing the unnatural amino acid phenylselenocysteine |
| EP2379578A4 (en) | 2009-01-12 | 2012-05-02 | Sutro Biopharma Inc | DOUBLE-LOADING SYSTEM FOR THE SELECTIVE INTRODUCTION OF NON-NITIVE AMINO ACIDS IN PROTEINS DUE TO AN IN VITRO-SYNTHESIS PROCESS |
| SG11201502875VA (en) * | 2012-10-12 | 2015-06-29 | Sutro Biopharma Inc | Proteolytic inactivation of select proteins in bacterial extracts for improved expression |
-
2013
- 2013-10-08 SG SG11201502875VA patent/SG11201502875VA/en unknown
- 2013-10-08 CA CA2887355A patent/CA2887355C/en active Active
- 2013-10-08 WO PCT/US2013/063804 patent/WO2014058830A1/en not_active Ceased
- 2013-10-08 KR KR1020157012291A patent/KR102018863B1/ko active Active
- 2013-10-08 CN CN201380063443.9A patent/CN104837863B/zh active Active
- 2013-10-08 HU HUE13779699A patent/HUE041721T2/hu unknown
- 2013-10-08 AU AU2013329464A patent/AU2013329464C1/en active Active
- 2013-10-08 JP JP2015536826A patent/JP6421122B2/ja active Active
- 2013-10-08 EP EP13779699.1A patent/EP2906592B1/en active Active
- 2013-10-08 DK DK13779699.1T patent/DK2906592T3/en active
- 2013-10-08 ES ES13779699.1T patent/ES2694683T3/es active Active
- 2013-10-08 PL PL13779699T patent/PL2906592T3/pl unknown
- 2013-10-08 US US14/434,391 patent/US9650621B2/en active Active
-
2015
- 2015-04-01 IL IL23809515A patent/IL238095B/en active IP Right Grant
-
2017
- 2017-04-10 US US15/483,766 patent/US10450353B2/en active Active
- 2017-11-29 JP JP2017229231A patent/JP2018029621A/ja not_active Withdrawn
-
2019
- 2019-09-06 US US16/562,837 patent/US11261219B2/en active Active
-
2020
- 2020-10-14 JP JP2020173282A patent/JP2021003134A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015531407A5 (cg-RX-API-DMAC7.html) | ||
| KR102018863B1 (ko) | 개선된 발현을 위해 박테리아 추출물 중 선택 단백질의 단백질분해 불활성화 | |
| JP7246100B2 (ja) | 新規融合タンパク質の調製およびそのタンパク質合成の向上における使用 | |
| JP2004532033A5 (cg-RX-API-DMAC7.html) | ||
| US20160251636A1 (en) | New methods to produce active tert | |
| RU2007141683A (ru) | Вариантная форма урат-оксидазы и ее использование | |
| JP6681625B2 (ja) | タンパク質の発現方法 | |
| EP2914282A1 (en) | Recombinant clostridium botulinum neurotoxins | |
| JPWO2016017631A1 (ja) | γ−グルタミルシステイン及びグルタチオンの製造方法 | |
| JP2020529221A5 (cg-RX-API-DMAC7.html) | ||
| JP2016507520A5 (cg-RX-API-DMAC7.html) | ||
| Connor et al. | Enzymatic N-terminal addition of noncanonical amino acids to peptides and proteins | |
| JPWO2020027010A5 (cg-RX-API-DMAC7.html) | ||
| JP3957630B2 (ja) | 組換えヒト副甲状腺ホルモンを生産する形質転換酵母及び該ホルモンの生産方法 | |
| CN110257347B (zh) | 硫氧还蛋白突变体、其制备方法及其在重组融合蛋白生产中的应用 | |
| Akaji et al. | Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant | |
| CN104387473A (zh) | 用于非酶切非色谱纯化方法原核表达融合蛋白Prx的类弹性蛋白多肽ELP | |
| CN101886068B (zh) | 一种固相化sumo化系统及固相化去sumo化系统 | |
| CN106701813A (zh) | 表达载体及其构建方法与应用 | |
| AU2016327453A1 (en) | Generation of peptides | |
| TW200531978A (en) | Removal of n-terminal methionine from proteins by engineered methionine aminopeptidase | |
| TWI591177B (zh) | 一種胰高血糖素胜肽－２（ｇｌｐ－２）類似物的製備方法 | |
| JP2015510770A5 (cg-RX-API-DMAC7.html) | ||
| EP4067492A1 (en) | Polypeptide tag and application thereof in in vitro protein synthesis | |
| Rao et al. | Cloning, soluble expression, and production of recombinant antihypertensive peptide multimer (AHPM-2) in Escherichia coli for bioactivity identification |